- Otonomy Inc OTIC announced top results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss.
- The trial demonstrated that a single intratympanic injection of 0.3 mg of OTO-413 provided clinically significant treatment benefit over placebo on multiple speech-in-noise (SIN) hearing tests and global impression change of patient at consecutive time points (days 57 and 85).
- 40% (8 of 20) of OTO-413 subjects demonstrated clinically meaningful improvement on at least one of the three SIN tests versus 20% (2 of 10) for placebo.
- Also see: Otonomy’s OTO-825 Gene Therapy May Restore Significant Hearing Function, Animal Study Shows.
- 15% (3 of 20) of OTO-413 subjects demonstrated clinically meaningful improvement by at least two different SIN tests versus 0% (0 of 10) for placebo.
- For the Words-in-Noise test, 40% (6 of 15 with evaluable tests) of OTO-413 subjects demonstrated clinically meaningful improvement compared to 0% (0 of 9 with evaluable tests) for placebo.
- Treatment with OTO-413 was well tolerated. 32% of OTO-413 subjects and 46% of placebo subjects reported an AE, most of which were mild.
- Otonomy intends to initiate a full dose-finding Phase 2 trial in patients with hearing loss by the end of 2022, incorporating learnings from ongoing higher dose evaluations evaluating two doses higher levels of OTO-413: 0.75 mg and 1.50 mg.
- The results of the highest dose assessment are expected in 2H of 2022.
- Price action: OTIC shares were up 0.46% at $2.11 in the last check trading session on Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
